60 Degrees Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.1M
- Price
- $1.44
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.60%
- Volume
- 629.4K
About
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
Quick stats
Shares outstanding3.5M
Computed float3.5M
Float / shares99.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001946563
AI Summary
AI-generated1/12
minorneutralother
60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
RedChip Companies will air sponsored interviews with Exyn Technologies and 60 Degrees Pharmaceuticals on its Small Stocks, Big Money show, airing on Bloomberg TV October 3 and CNBC October 4.
Exyn CEO Ben Williams discussed the company's GPS-denied autonomy and 3D mapping software, touting more than 1,000 autonomous missions per month, an expanding defense pipeline including Exyn Defense and Green UAS certification, and API/OEM software-licensing strategies.
The release is paid investor-relations promotion: RedChip discloses it is compensated by both companies, and no new material financial or operational information is announced.
Red flags
- Paid promotional content: RedChip receives compensation from EXYN and SXTP; information not independently verified
- Peak-sales and cumulative-revenue figures ($245M/$1.1B for SXTP) are forward-looking company estimates, not results